Cerus Corporation
$ 2.10
5.53%
04 Dec - close price
- Market Cap 382,254,000 USD
- Current Price $ 2.10
- High / Low $ 2.11 / 1.96
- Stock P/E N/A
- Book Value 0.32
- EPS -0.08
- Next Earning Report -
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.03 %
- ROE -0.28 %
- 52 Week High 2.23
- 52 Week Low 1.12
About
Cerus Corporation (CERS) is a leading biomedical products company dedicated to enhancing blood safety through its innovative INTERCEPT Blood System, which effectively inactivates pathogens in blood components. Based in Concord, California, Cerus employs cutting-edge technology to address the essential requirements of transfusion medicine, thereby ensuring improved patient safety. With a strong and expanding portfolio, the company is well-positioned to meet the growing global demand for safe blood products, while advancing blood safety protocols and making a meaningful contribution to public health initiatives.
Analyst Target Price
$4.67
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-10-30 | 2025-07-30 | 2025-04-30 | 2025-03-03 | 2024-10-30 | 2024-08-01 | 2024-05-02 | 2024-03-05 | 2023-11-02 | 2023-08-02 | 2023-05-04 | 2023-02-28 |
| Reported EPS | -0.0001 | -0.03 | -0.04 | -0.01 | -0.02 | -0.03 | -0.05 | -0.01 | -0.03 | -0.06 | -0.09 | -0.08 |
| Estimated EPS | -0.0267 | -0.0225 | -0.05 | -0.01 | -0.03 | -0.04 | -0.05 | -0.02 | -0.05 | -0.06 | -0.07 | -0.05 |
| Surprise | 0.0266 | -0.0075 | 0.01 | 0 | 0.01 | 0.01 | 0 | 0.01 | 0.02 | 0 | -0.02 | -0.03 |
| Surprise Percentage | 99.6255% | -33.3333% | 20% | 0% | 33.3333% | 25% | 0% | 50% | 40% | 0% | -28.5714% | -60% |
Next Quarterly Earnings
| Reported Date |
| Fiscal Date Ending |
| Estimated EPS |
| Currency |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: CERS
2025-11-02 11:25:36
Cerus Corporation reported strong second quarter 2025 financial results, including record product revenue of $52.4 million, a 16% increase year-over-year. The company raised its full-year 2025 product revenue guidance to $200 million-$203 million, driven by growth in IFC and global platelet sales. Cerus also achieved positive non-GAAP adjusted EBITDA for the quarter and is making progress in its product development pipeline.
2025-10-16 20:00:00
Cerus Corporation announced it will release its third quarter 2025 financial results on November 6, 2025, after the stock market closes. The company will host a conference call and webcast to discuss the results and provide a business overview. Cerus Corporation is dedicated to safeguarding the world's blood supply with its pathogen-protected blood components and INTERCEPT Blood System.
2025-10-12 07:13:45
Wealth Enhancement Advisory Services LLC has increased its stake in Cerus Corporation (CERS) by acquiring an additional 27,092 shares. Other institutional investors have also adjusted their positions in the biotechnology company, with several firms acquiring new stakes. Cerus Corporation operates as a biomedical products company, focusing on developing and commercializing the INTERCEPT Blood System to enhance blood safety.
2025-08-21 08:30:00
Cerus Corporation announced its participation in the Cantor Global Healthcare Conference 2025, with a fireside chat scheduled for September 3, 2025. A live webcast and replay will be available, highlighting the company's commitment to safeguarding the world's blood supply through its pathogen reduction technologies like the INTERCEPT Blood System. Cerus (Nasdaq: CERS) is a leader in blood safety technology, with products globally approved for platelets and plasma, and other systems under regulatory review or clinical development.
2025-08-08 00:00:00
Cerus Corporation (NASDAQ:CERS) recently released its second-quarter results, showing revenues in line with analyst forecasts but larger-than-expected losses. Analysts have subsequently cut their revenue estimates for 2025, although loss per share forecasts have been slightly upgraded. Despite these adjustments, the consensus price target for Cerus remains largely unchanged, indicating analysts believe the business is performing broadly as expected.
2025-07-21 12:30:00
Cerus Corporation has received an additional $7.2 million contract amendment from the U.S. Department of Defense to advance the development of lyophilized Pathogen Reduced, Cryoprecipitated Fibrinogen Complex (LyoIFC) for treating traumatic bleeding. This funding will support the CRYO-FIRST randomized study, comparing IFC to conventional cryoprecipitated antihemophilic factor in trauma patients with hemorrhagic shock. The overall goal is to provide a room-temperature, shelf-stable LyoIFC for use in austere environments to improve survival rates in both military and civilian trauma patients.
